Geron Corporation (LON:0IV3)

Market Cap	753.26M -48.3%
Revenue (ttm)	136.44M +522.1%
Net Income	-59.51M
EPS	-0.09
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,578
Average Volume	58,423
Open	1.568
Previous Close	1.638
Day's Range	1.550 - 1.640
52-Week Range	1.040 - 2.825
Beta	0.62
RSI	70.34
Earnings Date	Feb 25, 2026

About Geron

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1990
• Employees: 229
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IV3

Financial Performance

In 2024, Geron's revenue was $76.99 million, an increase of 32386.92% compared to the previous year's $237,000. Losses were -$174.57 million, -5.19% less than in 2023.

Financial numbers in USD